Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS ANNOUNCES AMENDMENT TO PRIVATE PLACEMENT PRICING

Onco-Innovations Ltd. has amended the pricing of its previously announced (see news release dated Jan. 23, 2026) non-brokered private placement. Under the amended private placement, the company intends to issue up to 3,076,9233 units at a price of 65 cents per unit, for aggregate gross proceeds of up to $2-million. Each unit will be composed of one common share and one share purchase warrant, with each warrant exercisable to acquire one share at a price of 75 cents for three years.

The company also intends to issue shares equal to 1.0 per cent of the total of shares issued in the amended private placement to an arm's-length third party, as an administrative fee, for its assistance with the amended private placement.

In connection with the amended private placement, the company may pay finders' fees and/or issue finders' warrants on the same terms as the warrants to eligible parties which introduce subscribers to the amended private placement.

Closing of the amended private placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to amended private placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. The company intends to use the proceeds of the amended private placement for general corporate and working capital purposes, including in pursuit of the company's operational and research and development objectives and for investor relations purposes.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.